Abstract
SFTI-1 is a bicyclic 14 amino acid peptide that was originally isolated from the seeds of the sunflower Helianthus annuus. It is a potent inhibitor of trypsin, with a sub-nanomolar Ki value and is homologous to the active site region of the well-known family of serine protease inhibitors known as the Bowman-Birk trypsin inhibitors. It has a cyclic backbone that is cross-braced by a single disulfide bridge and a network of hydrogen bonds that result in a well-defined structure. SFTI-1 is amenable to chemical synthesis, allowing for the creation of synthetic variants. Alterations to the structure such as linearising the backbone or removing the disulfide bridge do not reduce the potency of SFTI-1 significantly, and minimising the peptide to as few as nine residues results in only a small decrease in reactivity. The creation of linear variants of SFTI-1 also provides a tool for investigating putative linear precursor peptides. The mechanism of biosynthesis of SFTI-1 is not yet known but it seems likely that it is a gene-coded product that has arisen from a precursor protein that may be evolutionarily related to classic Bowman-Birk inhibitors.
Keywords: bowman-birk inhibitor, circular backbone, cyclic peptide, potent, sfti-1
Current Protein & Peptide Science
Title: Sunflower Trypsin Inhibitor-1
Volume: 5 Issue: 5
Author(s): Michael L.J. Korsinczky, Horst Joachim Schirra and David J. Craik
Affiliation:
Keywords: bowman-birk inhibitor, circular backbone, cyclic peptide, potent, sfti-1
Abstract: SFTI-1 is a bicyclic 14 amino acid peptide that was originally isolated from the seeds of the sunflower Helianthus annuus. It is a potent inhibitor of trypsin, with a sub-nanomolar Ki value and is homologous to the active site region of the well-known family of serine protease inhibitors known as the Bowman-Birk trypsin inhibitors. It has a cyclic backbone that is cross-braced by a single disulfide bridge and a network of hydrogen bonds that result in a well-defined structure. SFTI-1 is amenable to chemical synthesis, allowing for the creation of synthetic variants. Alterations to the structure such as linearising the backbone or removing the disulfide bridge do not reduce the potency of SFTI-1 significantly, and minimising the peptide to as few as nine residues results in only a small decrease in reactivity. The creation of linear variants of SFTI-1 also provides a tool for investigating putative linear precursor peptides. The mechanism of biosynthesis of SFTI-1 is not yet known but it seems likely that it is a gene-coded product that has arisen from a precursor protein that may be evolutionarily related to classic Bowman-Birk inhibitors.
Export Options
About this article
Cite this article as:
Korsinczky L.J. Michael, Schirra Joachim Horst and Craik J. David, Sunflower Trypsin Inhibitor-1, Current Protein & Peptide Science 2004; 5 (5) . https://dx.doi.org/10.2174/1389203043379594
DOI https://dx.doi.org/10.2174/1389203043379594 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Medicinal Plants: A Natural Chaperones Source for Treating Neurological Disorders
Protein & Peptide Letters Toxicity of Carbon Nanotubes
Current Drug Metabolism Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets TGF-β Pathway as a Potential Target in Neurodegeneration and Alzheimers
Current Alzheimer Research The Neuroprotective Role of PEDF: Implication for the Therapy of Neurological Disorders
Current Molecular Medicine Multiple Sclerosis Therapy Monitoring Based on Gene Expression
Current Pharmaceutical Design Evolving Therapeutic Targets in Ischemic Stroke: A Concise Review
Current Drug Targets AMPA Receptor Antagonists: Potential Therapeutic Applications
Recent Patents on CNS Drug Discovery (Discontinued) Editorial (Hot Topic:Therapeutic Agents of Lipids and Fatty Acids)
Current Organic Chemistry Indolo[2,3-a]quinolizidines and Derivatives: Bioactivity and Asymmetric Synthesis
Current Pharmaceutical Design Mining the Genome for Susceptibility to Complex Neurological Disorders
Current Molecular Medicine Advances in Antioxidative Therapy of Multiple Sclerosis
Current Medicinal Chemistry IL-17A and Multiple Sclerosis: Signaling Pathways, Producing Cells and Target Cells in the Central Nervous System
Current Drug Targets Tianeptine: A Novel Atypical Antidepressant that May Provide New Insights into the Biomolecular Basis of Depression
Recent Patents on CNS Drug Discovery (Discontinued) Indoles and Related Compounds as Cannabinoid Ligands
Mini-Reviews in Medicinal Chemistry Targeting Generation of Antibodies Specific to Conformational Epitopes of Amyloid β-Derived Neurotoxins
CNS & Neurological Disorders - Drug Targets Fluorescent Proteins as Biomarkers and Biosensors: Throwing Color Lights on Molecular and Cellular Processes
Current Protein & Peptide Science Gene Therapy for Parkinsons Disease: Progress and Challenges
Current Gene Therapy Scope of Lipid Nanoparticles in Neuroscience: Impact on the Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Editorial (Thematic Issue: Molecular and Cellular Engineering Approaches for Neurological Disorders, Diseases, and Injuries Involved the Central and Peripheral Nervous Systems)
CNS & Neurological Disorders - Drug Targets